envolve Pharmacy Solutions

pa health & wellness

Prior Authorization Request Form for Botulinum Toxins

FAX this completed form to (877) 386-4695

OR Mail requests to: Envolve Pharmacy Solutions PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720

I. PROVIDER INFORMATION	II. MEMBER INFORMATION
Prescriber Name:	Member Name:
Prescriber Specialty:	Identification #:
Office Contact Name:	Group #:
Group Name:	Date of Birth:
Fax #:	Medication Allergies:
Phone #:	

III. DRUG INFORMATION (One drug request per form)		
Drug name and strength:	Dosage Interval (sig):	Qty. Requested:

Please list treatment plan including proposed injection sites and dose that will be injected into each site:

Dates of previous injections:

IV. REQUIRED DOCUMENTION *(Detailed medical record documentation demonstrating evidence for each item must be submitted with prior authorization request)*

Specify diagnosis & diagnosis code relevant to this request: Dx/Dx Code: _____

Does the member have a history of contraindication to the prescribed medication?	☐ Yes ☐ No	*Submit documentation.*
Requests for all non-preferred medications: Does the member have a history of trial and failure of or contraindication or intolerance to the preferred Botulinum Toxins? *Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred medications in this class.*	☐ Yes ☐ No	*Submit documentation of previous trials/failures, contraindications, and/or intolerances or current use.*

- ☐ Member is not pregnant or breastfeeding
- ☐ If requesting for daily quantity exceeding daily limit (Refer to https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx), please provide supporting information:_____

SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.

CHRONIC SPASTICITY:

- ☐ Spasticity is a result from:
  □Cerebral Palsy □Multiple Sclerosis □Traumatic Brain Injury □Spinal Cord Injury □Stroke
- ☐ Member has documented spasticity that:
  - ☐ Interferes with daily living, evidenced by:_____
  - ☐ Is expected to result in joint contracture with future growth:_____
- ☐ For member age 18 or older, has documented therapeutic failure, contraindication or intolerance to at least 1 oral medication for spasticity (medication, start date and end date):_____
- ☐ If member has developed contractures, they have been considered for surgical intervention
- ☐ Botulinum toxin is requested to:
  - ☐ Enhance function:_____
  - ☐ Allow for additional therapeutic modalities:_____

- ☐ Botulinum toxin will be used in conjunction with other appropriate therapeutic modalities (physical therapy, occupational therapy, gradual splinting, etc):_____

STRABISMUS:

- ☐ Member has a deviation of less than 50 prism diopters, please list deviation:_____
- ☐ Treatment has the potential to restore binocular vision
- ☐ Strabismus is NOT due to Duane's Syndrome with lateral rectus muscle weakness, restrictive strabismus or secondary strabismus caused by prior surgery

AXILLARY HYPERHIDROSIS:

- ☐ Documented history of therapeutic failure, contraindication or intolerance to a topical agent (Aluminum Chloride 20%): (medication, start date and end date)_____

CHRONIC MIGRAINE:

- ☐ Member has a history of chronic migraine headache not attributed to other causes including medication overuse:
  - ☐ Headache (tension-type and/or migraine) on at least 15 days per month for at least 3 months:_____
  - ☐ At least 5 of these attacks meet at least 2 of the following
    - ☐ Unilateral location
    - ☐ Pulsating quality
    - ☐ Moderate to severe intensity
    - ☐ Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs)
- ☐ During headache, at least one of the following is present:
  - ☐ Nausea and/or vomiting
  - ☐ Photophobia and Phonophobia
  - ☐ Headaches are treated and relieved by triptans or ergotamine(s) before the expected development of associated
  - ☐ symptoms of migraines
- ☐ Documented history of therapeutic failure, contraindication or intolerance to at least 3 of the following: (medication, start date and end date)
  - ☐ Beta-Blocker (e.g. metoprolol, propranolol, timolol):_____
  - ☐ Antidepressant (e.g. amitriptyline, venlafaxine):_____
  - ☐ Anticonvulsant (e.g. topiramate, valproic acid, divalproex):_____
  - ☐ Calcium Channel Blocker (e.g. verapamil):_____

URINARY INCONTINENCE DUE TO DETRUSOR OVERACTIVITY ASSOCIATED WITH NEUROLOGIC CONDITION:

- ☐ Documented history of therapeutic failure, contraindication or intolerance to at least 2 agents used to treat urinary incontinence: (medication, start date and end date)_____

OVERACTIVE BLADDER:

- ☐ Member has overactive bladder with symptoms of urge urinary incontinence, urgency and frequency
- ☐ Documented history of therapeutic failure, contraindication or intolerance to at least 2 agents used to treat overactive bladder: (medication, start date and end date)_____

RENEWAL REQUEST:

- ☐ Request exceeds the recommended FDA dosing and duration of therapy:
  - ☐ Previous treatment was well tolerated but inadequate
  - ☐ Medical literature supports more frequent dosing intervals as safe and effective for the diagnosis and requested dose
- ☐ Request is consistent with the recommended FDA dosing and duration of therapy:
  - ☐ Previous treatment was well tolerated and the member showed evidence of measurable improvement in severity of symptoms
  - ☐ Symptoms returned to such a degree that repeat injection is required

IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :

Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)